PEDIATRIC PHARMACOTHERAPY

A Monthly Review for Health Care Professionals
of the Children's Medical Center

Volume 3, Number 1, January 1997

Two-Year Index for Pediatric Pharmacotherapy

The following index has been prepared from key terms used in Pediatric Pharmacotherapy over the past two years. The first column indicates volume and issue numbers with a symbol indicating the type of citation. In this index, L= literature review (abstract), M= main (feature) article, and F= FDA update. The second column provides month and year of publication.

A|B|C|D|E|F|G|H|I|J|K|L|M|N|O|P|Q|R|S|T|U|V|W|X|Y|Z

A

Acetaminophen; volume 2, number 7 (M 7/96)

Acetaminophen, renal effects; volume 1, number 6 (L 6/95)

Aclometasone; volume 2, number 1 (M 1/96)

Aclovateâ ; volume 2, number 1 (M 1/96)

Acute pain, management; volume 2, number 6 (L 6/96)

Adverse drug reactions, frequency in children; volume 2, number 10 (L 10/96)

Adverse drug reactions, reporting; volume 1, number 3 (M 3/95)

Adverse effects, causality; volume 2, number 11 (L 11/96)

Albuterol ; volume 2, number 5 (M 5/96)

Amcinonide; volume 2, number 1 (M 1/96)

Angiotensin-converting enzyme inhibitors; volume 2, number 2 (L 2/96)

Antibiotics, allergies; volume 1, number 12 (L 12/95)

Antibiotics, comparison of oral; volume 2, number 4 (L 4/96)

Anticonvulsants, developments; volume 2, number 11 (L 11/96)

Anticonvulsants, pharmacokinetics Part I; volume 1, number 12 (L 12/95)

Anticonvulsants, pharmacokinetics Part II; volume 2, number 1 (L 1/96)

Antihistamines; volume 1, number 9 (M 9/95)

Antipyretics; volume 2, number 7 (M 7/96)

Astemizole; volume 1, number 9 (M 9/95)

Asthma, steroids; volume 1, number 1 (L 1/95)

Asthma, therapy in adolescents; volume 1, number 8 (L 8/95)

Atenolol, use in Marfan syndrome; volume 1, number 5 (L 5/95)

Atropine; volume 2, number 12 (M12/96)

Attention deficit/hyperactivity disorder, therapy; Volume 1, number 12 (M12/95)

Autism, medications; volume 1, number 2 (L 2/95)

Azithromycin; volume 2, number 2 (M 2/96)

B

Benadrylâ ; volume 1, number 9 (M 9/95)

Benzalkonium chloride;  volume 2, number 9 (M 9/96)

Benzyl alcohol; volume 2, number 9 (M 9/96)

Betamethasone; volume 2, number 1 (M 1/96)

Biaxinâ ; volume 2, number 2 (M 2/96)

Breastfeeding, effects of drugs on neonatal hepatic function; volume 2, number 4 (M 4/96)

Breastfeeding, effects of drugs during; volume 1, number 12 (L 12/95)

Brompheniramine; volume 1, number 9 (M 9/95)

Bumetanide; volume 1, number 10 (M10/95)

C

Caffeine; volume 1, number 3 (L 3/95)

Calcium chloride; volume 2, number 12 (M12/96)

Carbamazepine; volume 2, number 11 (M11/96)

Carbamazepine, cyclosporine interaction; volume 1, number 6 (L 6/96)

Carbamazepine, drug interactions; volume 2, number 10 (L 10/96)

Carbamazepine, Stevens-Johnson syndrome; volume 1, number 6 (L 6/96)

Cardiovascular drugs, pharmacokinetics; volume 1, number 1 (L 1/95)

Ceclorâ ; volume 2, number 6 (M 6/96)

Cedaxâ ; volume 2, number 6 (M 6/96)

Cefaclor; volume 2, number 6 (M 6/96)

Cefadroxil; volume 2, number 6 (M 6/96)

Cefixime, therapy review; volume 1, number 8 (L 8/95)

Cefixime; volume 2, number 6 (M 6/96)

Cefpodoxime; volume 2, number 6 (M 6/96)

Cefprozil; volume 2, number 6 (M 6/96)

Ceftazidime; volume 1, number 4 (L 4/95)

Ceftazidime, use in infants; volume 2, number 2 (L 2/96)

Ceftibuten; volume 2, number 6 (M 6/96)

Ceftinâ ; volume 2, number 6 (M 6/96)

Cefuroxime axetil; volume 2, number 6 (M 6/96), Cefuroxime axetil, therapy review 2(7)L 7/96

Cefzilâ; volume 2, number 6 (M 6/96)

Cephalexin; volume 2, number 6 (M 6/96)

Cephalosporins, review of oral; volume 2, number 6 (M 6/96)

Cephradine; volume 2, number 6 (M 6/96)

Children’s Motrinâ; volume 2, number 7 (M 7/96)

Chlorothiazide; volume 1, number 10 (M10/95)

Chlorpheniramine; volume 1, number 9 (M 9/95)

Chlor-Trimetonâ; volume 1, number 9 (M 9/95)

Cisapride, drug interactions; volume 2, number 11 (L 11/96)

Clarithromycin; volume 2, number 2 (M 2/96)

Claritinâ ; volume 1, number 9 (M 9/95)

Clearance;volume 1, number 7 (M 7/95)

Clemastine; volume 1, number 9 (M 9/95)

Clobetasol; volume 2, number 1 (M 1/96)

Clocortolone; volume 2, number 1 (M 1/96)

Clodermâ ; volume 2, number 1 (M 1/96)

Clonazepam, pharmacokinetics; volume 2, number 3 (L 3/96)

Clonidine; volume 1, number 12 (M12/95)

Compliance with medications; volume 1, number 4 (L 4/95)

Conscious sedation; volume 2, number 3 (L 3/96)

Cordranâ ; volume 2, number 1 (M 1/96)

Cortaidâ ; volume 2, number 1 (M 1/96)

Corticosteroids, topical; volume 2, number 1 (M 1/96)

Cortizoneâ ; volume 2, number 1 (M 1/96)

Coumadinâ ; volume 1, number 1 (M 1/95)

Creatinine clearance, prediction; volume 1, number 10 (L 10/95)

Crotamiton; volume 1, number 8 (M 8/95)

Cutivateâ ; volume 2, number 1 (M 1/96)

Cyclic antidepressant toxicity; volume 1, number 5 (L 5/95)

Cyclocortâ ; volume 2, number 1 (M 1/96)

Cyclosporine; volume 1, number 4 (M 4/95)

Cyclosporine, absorption; volume 2, number 3 (L 3/96)

Cyclosporine, carbamazepine interaction; volume 1, number 6 (L 6/95)

Cyclosporine, drug interactions; volume 2, number 4 (L 4/96)

Cyclosporine, norfloxacin interaction; volume 1, number 11 (L 11/95)

Cystic fibrosis, drug metabolism; volume 1, number 1 (L 1/95)

Cystic fibrosis, therapy of complications; volume 1, number 11 (L 11/95)

Cystic fibrosis, tobramycin pharmacokinetics; volume 2, number 5 (L 5/96)

Cytochrome P450 enzymes; volume 1, number 7 (L 7/95)

D

Decadronâ ; volume 2, number 1 (M 1/96)

Desonide; volume 2, number 1 (M 1/96)

Desoximetasone; volume 2, number 1 (M 1/96)

Dexamethasone; volume 2, number 1 (M 1/96)

Dextroamphetamine; volume 1, number 12 (M 12/95)

Diflorasone; volume 2, number 1 (M 1/96)

Digoxin, drug interactions; volume 1, number 4 (L 4/95)

Dilantinâ ; volume 2, number 8 (M 8/96)

Dilution of medications for neonates; volume 1, number 8 (L 8/95)

Dimetaneâ ; volume 1, number 9 (M 9/95)

Diphenhydramine; volume 1, number 9 (M 9/95)

Diprolene AFâ; volume 2, number 1 (M 1/96)

Diprosoneâ ; volume 2, number 1 (M 1/96)

Diuretics; volume 1, number 10 (M10/95)

Dornase alpha; volume 1, number 1 (L 1/95)

Dornase alpha, cost-benefit analysis; volume 1, number 6 (L 6/95)

Dornase alpha, update; volume 2, number 3 (L 3/96)

Drug approval process, FDA; volume 1, number 11 (M11/95)

Drug-nutrient interactions; volume 1, number 5 (M 5/95)

Drug reactions, idiosyncratic; volume 2, number 10 (L10/96)

Duricefâ ; volume 2, number 6 (M 6/96)

Dyes and colorants, pharmaceutical; volume 2, number 9 (M 9/96)

E

Eloconâ ; volume 2, number 1 (M 1/96)

EMLA, use with subcutaneous infusions; volume 1, number 5 (L 5/95)

Epilepsy, diagnosis and treatment; volume 2, number 4 (L 4/96)

Epinephrine; volume 2, number 12 (M12/96)

Epoetin; volume 1, number 3 (L 3/95)

Erythromycin; volume 2, number 2 (M 2/96)

Ethanol; volume 2, number 9 (M 9/96)

Etoposide, pharmacokinetics and pharmacodynamics; volume 1, number 9 (L 9/95)

Excipients, pharmaceutical; volume 2, number 9 (M 9/96)

F

Famotidine; ; volume 2, number 9 (L 9/96)

Famotidine, pharmacokinetics and pharmacodynamics; volume 2, number 3 (L 3/96)

Flavorings, pharmaceutical; volume 2, number 9 (M 9/96)

Floroneâ ; volume 2, number 1 (M 1/96)

Fluconazole, interaction with warfarin; volume 2, number 5 (L 5/96)

Fluconazole, pharmacokinetics; volume 1, number 2 (L 2/95)

Fluocinolone; volume 2, number 1 (M 1/96)

Fluocinonide; volume 2, number 1 (M 1/96)

Fluoxetine; volume 2, number 10 (M10/96)

Flurandrenolide; volume 2, number 1 (M 1/96)

Fluticasone; volume 2, number 1 (M 1/96)

Fluvoxamine; volume 2, number 10 (M10/96)

Food and Drug Administration, drug approval process; volume 1, number 11 (M11/95)

Furosemide; volume 1, number 10 (M10/95)

G

G-CSF; volume 1, number 1 (L 1/95)

G-CSF, binding to catheters; volume 1, number 2 (L 2/95)

Gentamicin, dosing in neonates; volume 1, number 7 (L 7/95)

Gentamicin, pharmacokinetics in children with cancer; volume 2, number 1 (L 1/96)

Gestational diabetes, management; volume 2, number 7 (L 7/96)

H

Halcinonide; volume 2, number 1 (M 1/96)

Half-life; volume 1, number 7 (M 7/95)

Halobetasol; volume 2, number 1 (M 1/96)

Halogâ ; volume 2, number 1 (M 1/96)

Hismanalâ ; volume 1, number 9 (M 9/95)

HIV, therapy in children; volume 1, number 6 (L 6/95)

Hydrochlorothiazide; volume 1, number 10 (M10/95)

Hydrocortisone; volume 2, number 1 (M 1/96)

Hypertension, treatment; volume 1, number 1 (L 1/95)

I

Ibuprofen, overdose; volume 1, number 10 (L 10/95)

Ibuprofen, review; volume 2, number 7 (M 7/96)

Idiosyncratic drug reactions; volume 2, number 10 (L 10/96)

Imipenem/cilastatin; volume 2, number 2 (L 2/96)

Immune globulin, use in pediatric AIDS; volume 1, number 5 (L 5/95)

INR; volume 1, number 1 (M 1/95)

Isoniazid; volume 1, number 2 (L 2/95)

J-K

Keflexâ; volume 2, number 6 (M 6/96)

Kenalogâ ; volume 2, number 1 (M 1/96)

Kwellâ ; volume 1, number 8 (M 8/95)

L

Lamotrigine; volume 1, number 3 (L 3/95)

Lamotrigine, update; volume 1, number 12 (L 12/95)

Lice, treatment; volume 1, number 8 (M 8/95)

Lidexâ ; volume 2, number 1 (M 1/96)

Lindane; volume 1, number 8 (M 8/95)

Lorabidâ; volume 2, number 6 (M 6/96)

Loracarbef ; volume 2, number 6 (M 6/96)

Loratadine; volume 1, number 9 (M 9/95)

Luvoxâ; volume 2, number 10 (M 10/96)

M

Macrolides, drug interactions; volume 1, number 9 (L 9/95)

Macrolides, review; volume 2, number 2 (M 2/96)

Malathion; volume 1, number 8 (M 8/95)

Maxiflorâ ; volume 2, number 1 (M 1/96)

Medication errors, prevention; volume 1, number 1 (L 1/95)

MedWatch; volume 1, number 3 (M 3/95)

MedWatch, data from; volume 1, number 8 (L 8/95)

Methemoglobinemia, drug-induced; volume 2, number 8 (L 8/96)

Methotrexate, pharmacokinetics; volume 1, number 4 (L 4/95)

Methylphenidate; volume 1, number 12 (M12/95)

Metoclopramide; volume 1, number 3 (L 3/95)

Metolazone; volume 1, number 10 (M10/95)

Midazolam, clearance in children; volume 2, number 2 (L 2/96)

Midazolam, compatibility; volume 1, number 12 (L 12/95)

Midazolam, intranasal; volume 2, number 5 (L 5/96)

Midazolam, use in neonates; volume 1, number 2 (L 2/95)

Milk:Plasma ratio; volume 2, number 4 (M 4/96)

Mometasone; volume 2, number 1 (M 1/96)

Moricizine; volume 1, number 12 (L 12/95)

Morphine, use in neonates; volume 1, number 1 (L 1/95)

N

Naloxone; volume 2, number 12 (M12/96)

New drug development; volume 1, number 7 (L 7/95)

Non-prescription medications; volume 1, number 5 (L 5/95)

Nonsteroidal anti-inflammatory drugs, renal effects; volume 1, number 6 (L 6/96)

Norfloxacin, cyclosporine interaction; volume 1, number 11 (L 11/95)

O

Ondansetron, outpatient use; volume 1, number 2 (L 2/95)

Ondansetron, pharmacokinetics; volume 1, number 11 (L 11/95)

Opiates, respiratory depression; volume 2, number 3 (L 3/96)

Oral contraceptives; volume 1, number 3 (L 3/95)

P

Pain management; volume 2, number 3 (L 3/96)

Pain, management of acute; volume 2, number 6 (L 6/96)

Parenteral nutrition;volume 1, number 3 (L 3/95)

Paroxetine; volume 2, number 10 (M10/96)

Paxilâ ; volume 2, number 10 (M10/96)

Pediatric pharmacology library; volume 1, number 6 (M 6/95)

Pemoline; volume 1, number 12 (M12/95)

Pemoline, liver failure; volume 1, number 8 (L 8/95)

Permethrin; volume 1, number 8 (M 8/95)

Pharmaceutical excipients; volume 2, number 9 (M 9/96)

Phenytoin; volume 2, number 8 (M 8/96)

Placebo response; volume 2, number 11 (L11/96)

Placental drug transfer, antipyrine model; volume 2, number 1 (L 1/96)

Placental drug transfer, mechanisms; volume 1, number 4 (L 4/95)

Poison Prevention; volume 1, number 3 (M 3/95), volume 2, number 3 (M 3/96)

Polyethylene glycol; volume 2, number 9 (M 9/96)

Preservatives, pharmaceutical ; volume 2, number 9 (M 9/96)

Propylene glycol; volume 2, number 9 (M 9/96)

Prozacâ ; volume 2, number 10 (M10/96)

Psychiatric disorders, treatment; volume 2, number 6 (L 6/96)

Psychotropic use, predicting; volume 2, number 9 (L 9/96)

Propofol, use in intensive care; volume 1, number 12 (L 12/95)

Pyrethrins; volume 1, number 8 (M 8/95)

Q-R

Recent advances in pharmacology; volume 1, number 2 (L 2/95)

Risperidone, toxicity; volume 2, number 5 (L 5/96)

S

Salmeterol; volume 1, number 1 (F 1/95)

Scabies, treatment; volume 1, number 8 (M 8/95)

Scabies, treatment update; volume 2, number 8 (L 8/96)

Seldaneâ ; volume 1, number 9 (M 9/95)

Selective serotonin reuptake inhibitors; volume 2, number 10 (M10/96)

Sereventâ ; volume 1, number 1 (F 1/95)

Sertraline; volume 2, number 10 (M10/96)

Skin reactions, drug-induced; volume 1, number 9 (L 9/95)

Smoking cessation; volume 1, number 3 (L 3/95)

Sodium bicarbonate; volume 2, number 12 (M12/96)

Solvents, pharmaceutical; volume 2, number 9 (M 9/96)

Spironolactone; volume 1, number 10 (M10/95)

Sufentanil, intranasal; volume 2, number 5 (L 5/96)

Supraxâ; volume 2 number 6 (M 6/96)

Surfactant; volume 2, number 3 (L 3/96)

Sweeteners, pharmaceutical; volume 2, number 9 (M 9/96)

Synalarâ ; volume 2, number 1 (M 1/96)

T

Tavist-Dâ ; volume 1, number 9 (M 9/95)

Tegretolâ ; volume 2, number 11 (M11/96)

Temovateâ ; volume 2, number 1 (M 1/96)

Terfenadine; volume 1, number 9 (M 9/95)

Terfenadine, transfer into breastmilk; volume 1, number 5 (L 5/95)

Theophylline, dosing equations; volume 1, number 4 (L 4/95)

Theophylline, dosing guidelines; volume 1, number 9 (L 9/95)

Theophylline, drug interactions; volume 1, number 5 (L 5/95)

Therapeutic drug monitoring; volume 1, number 7 (M 7/95)

Therapeutic equivalence; volume 2, number 12 (L12/96)

Ticarcillin/clavulanic acid, dosing; volume 1, number 9 (L 9/95)

Tobramycin, pharmacokinetics in cystic fibrosis; volume 2, number 5 (L 5/96)

Topicortâ ; volume 2, number 1 (M 1/96)

Triamcinolone; volume 2, number 1 (M 1/96)

Tridesilonâ ; volume 2, number 1 (M 1/96)

Tylenolâ ; volume 2, number 7 (M 7/96)

U

Ultravateâ ; volume 2, number 1 (M 1/96)

Uticortâ ; volume 2, number 1 (M 1/96)

V

Vaccine Adverse Event Reporting System (VAERS); volume 1, number 3 (M 3/95)

Vaccines, storage; volume 1, number 6 (M 6/96)

Valisoneâ ; volume 2, number 1 (M 1/96)

Valproate, pharmacokinetics; volume 1, number 12 (L12/95)

Vancomycin; volume 1, number 2 (M 2/95)

Vancomycin-resistent enterococci; volume 1, number 2 (M 2/95)

Vantinâ ; volume 2, number 6 (M 6/96)

Varicella vaccine; volume 1, number 7 (F 7/95)

Velosefâ ; volume 2, number 6 (M 6/96)

Vitamin K; volume 1, number 4 (L 4/95)

Volume of distribution; volume 1, number 7 (M 7/95)

W

Warfarin; volume 1, number 1 (M 1/95)

Warfarin, interaction with fluconazole; volume 2, number 5 (L 5/96)

Westcortâ; volume 2, number 1 (M 1/96)

X-Z

Zidovudine, use in pregnancy; volume 1, number 8 (L 8/95)

Zithromaxâ; volume 2, number 2 ( M 2/96)

Zoloftâ ; volume 2, number 10 (M10/96)

RETURN TO TOP

All contents copyright (C)1997, Stephen M. Borowitz. All rights reserved
Revised: March 1, 1997